CN112587587A - Preparation method of pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus - Google Patents
Preparation method of pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus Download PDFInfo
- Publication number
- CN112587587A CN112587587A CN202110023053.5A CN202110023053A CN112587587A CN 112587587 A CN112587587 A CN 112587587A CN 202110023053 A CN202110023053 A CN 202110023053A CN 112587587 A CN112587587 A CN 112587587A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- lupus erythematosus
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940040145 liniment Drugs 0.000 title claims abstract description 32
- 239000000865 liniment Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 206010025135 lupus erythematosus Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 23
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 22
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 22
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 22
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 22
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 22
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 22
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 22
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 22
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000010231 banlangen Substances 0.000 claims abstract description 15
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 14
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 13
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 10
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract description 9
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 9
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims abstract description 9
- 241000915604 Scutellaria barbata Species 0.000 claims abstract description 9
- 241000334160 Isatis Species 0.000 claims abstract description 8
- 241000405414 Rehmannia Species 0.000 claims abstract description 8
- 239000011812 mixed powder Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000004570 mortar (masonry) Substances 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 6
- 239000004575 stone Substances 0.000 claims abstract description 6
- 244000081426 Ranunculus ficaria Species 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 22
- 230000000857 drug effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 12
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 241001530126 Scrophularia Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000001816 cooling Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000234295 Musa Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus and a preparation method thereof, wherein the pure traditional Chinese medicine transdermal liniment comprises the following raw materials in parts by weight: 14-20 parts of radix rehmanniae, 12-20 parts of radix scrophulariae, 15-20 parts of honeysuckle, 15-20 parts of radix isatidis, 12-20 parts of sculellaria barbata, 15-20 parts of cape jasmine, 12-20 parts of cortex moutan, 13-20 parts of salvia miltiorrhiza, 12-18 parts of semen plantaginis and 15-20 parts of oriental wormwood; the preparation method of the transdermal liniment comprises the following steps: (1) putting the dried rehmannia root, the figwort root, the honeysuckle, the isatis root, the barbed skullcap herb, the gardenia, the cortex moutan, the salvia miltiorrhiza bunge, the plantain seed and the oriental wormwood in the stone mortar according to the weight parts, and pounding the mixture into powder; (2) the mashed mixed powder is put into 50 to 100 weight parts of alcohol to be soaked for 20 to 25 days for use. The invention has the advantages of safe raw materials, reasonable proportion, obvious treatment effect, simple preparation method and better drug effect of the raw materials.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a preparation method of a pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus.
Background
At present, most of medicines for treating lupus erythematosus are oral western medicines or traditional Chinese medicines, the western medicines have great side effects and are easy to generate drug resistance, the existing traditional Chinese medicines for treating lupus erythematosus are all oral medicines and need to be decocted, and the raw materials and the proportion are not good, so that the treatment effect is not obvious.
Disclosure of Invention
The pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus is prepared from traditional Chinese medicines, is safe in raw materials, reasonable in proportion, small in side effect, obvious in treatment effect and low in treatment cost, and does not produce drug resistance.
In order to achieve the first purpose, the invention adopts the following technical scheme:
a pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus comprises the following raw materials in parts by weight: 14-20 parts of radix rehmanniae, 12-20 parts of radix scrophulariae, 15-20 parts of honeysuckle, 15-20 parts of radix isatidis, 12-20 parts of herba scutellariae barbatae, 15-20 parts of cape jasmine, 12-20 parts of cortex moutan, 13-20 parts of salvia miltiorrhiza, 12-18 parts of semen plantaginis and 15-20 parts of oriental wormwood.
Preferably, the feed comprises the following raw materials in parts by weight: 14 parts of radix rehmanniae, 12 parts of radix scrophulariae, 15 parts of honeysuckle, 15 parts of radix isatidis, 12 parts of sculellaria barbata, 15 parts of cape jasmine, 12 parts of cortex moutan, 13 parts of salvia miltiorrhiza, 12 parts of semen plantaginis and 15 parts of oriental wormwood.
Preferably, the feed comprises the following raw materials in parts by weight: 17 parts of radix rehmanniae, 15 parts of radix scrophulariae, 17 parts of honeysuckle, 17 parts of radix isatidis, 16 parts of sculellaria barbata, 18 parts of cape jasmine, 17 parts of cortex moutan, 16 parts of salvia miltiorrhiza, 15 parts of semen plantaginis and 18 parts of oriental wormwood.
Preferably, the feed comprises the following raw materials in parts by weight: 20 parts of radix rehmanniae, 20 parts of radix scrophulariae, 20 parts of honeysuckle, 20 parts of radix isatidis, 20 parts of sculellaria barbata, 20 parts of cape jasmine, 20 parts of cortex moutan, 20 parts of salvia miltiorrhiza, 18 parts of semen plantaginis and 20 parts of oriental wormwood.
The invention aims to provide a pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus and a preparation method thereof.
In order to achieve the second object, the invention adopts the following technical scheme:
a method for preparing a pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus comprises the following steps:
(1) putting the dried rehmannia root, the figwort root, the honeysuckle, the isatis root, the barbed skullcap herb, the gardenia, the cortex moutan, the salvia miltiorrhiza bunge, the plantain seed and the oriental wormwood in the stone mortar according to the weight parts, and pounding the mixture into powder;
(2) the mashed mixed powder is put into 50 to 100 weight parts of alcohol to be soaked for 20 to 25 days for use.
Preferably, the alcohol concentration in step (2) is 75%.
The raw materials in the invention have the following effects:
radix rehmanniae: has the effects of clearing heat, cooling blood, nourishing yin and promoting the production of body fluid.
Figwort root: has the effects of clearing heat, cooling blood, nourishing yin, lowering fire, detoxifying and resolving masses.
Honeysuckle flower: has effects of clearing away heat and toxic materials, dispelling pathogenic wind and heat, cooling blood, and relieving dysentery.
Radix isatidis: has the effects of clearing away heat and toxic materials, cooling blood and relieving sore throat.
Barbed skullcap herb: has the effects of clearing away heat and toxic materials, promoting blood circulation, dispelling blood stasis, inducing diuresis, and relieving swelling.
Gardenia: has effects of clearing heat, purging pathogenic fire, and cooling blood.
Cortex moutan: has effects of clearing heat, cooling blood, promoting blood circulation, removing blood stasis, and relieving deficiency heat.
Radix salviae miltiorrhizae: has effects of promoting blood circulation, regulating menstruation, removing blood stasis, and relieving pain.
Plantain seed: has effects of clearing heat, promoting diuresis, eliminating dampness, relieving diarrhea, eliminating phlegm, and relieving cough.
Herba artemisiae scopariae: has effects of clearing heat, promoting diuresis, eliminating jaundice, promoting bile flow, and protecting liver.
The invention has the beneficial effects that: the pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus and the preparation method thereof select the raw materials of the rehmannia root, the figwort root, the honeysuckle, the isatis root, the barbed skullcap herb, the gardenia, the cortex moutan, the salvia miltiorrhiza, the plantain seed and the oriental wormwood, and have the advantages of safe raw materials and reasonable proportion, so that the pure traditional Chinese medicine transdermal liniment has the function of treating the lupus erythematosus, does not generate drug resistance, has small toxic and side effects and obvious treatment effect, and is convenient to use by adopting a liniment mode; the preparation method has simple steps, and the raw materials are fully fused by using alcohol, so that the drug effect is better exerted.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example one
A pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus comprises the following raw materials in parts by weight: 14 parts of radix rehmanniae, 12 parts of radix scrophulariae, 15 parts of honeysuckle, 15 parts of radix isatidis, 12 parts of sculellaria barbata, 15 parts of cape jasmine, 12 parts of cortex moutan, 13 parts of salvia miltiorrhiza, 12 parts of semen plantaginis and 15 parts of oriental wormwood.
The preparation method of the pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus comprises the following steps:
(1) putting the dried rehmannia root, the figwort root, the honeysuckle, the isatis root, the barbed skullcap herb, the gardenia, the cortex moutan, the salvia miltiorrhiza bunge, the plantain seed and the oriental wormwood in the stone mortar according to the weight parts, and pounding the mixture into powder;
(2) the mashed mixed powder is put into 50 parts by weight of 75% alcohol to be soaked for 20 days.
Example two
A pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus comprises the following raw materials in parts by weight: 17 parts of radix rehmanniae, 15 parts of radix scrophulariae, 17 parts of honeysuckle, 17 parts of radix isatidis, 16 parts of sculellaria barbata, 18 parts of cape jasmine, 17 parts of cortex moutan, 16 parts of salvia miltiorrhiza, 15 parts of semen plantaginis and 18 parts of oriental wormwood.
The preparation method of the pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus comprises the following steps:
(1) putting the dried rehmannia root, the figwort root, the honeysuckle, the isatis root, the barbed skullcap herb, the gardenia, the cortex moutan, the salvia miltiorrhiza bunge, the plantain seed and the oriental wormwood in the stone mortar according to the weight parts, and pounding the mixture into powder;
(2) and (3) putting the mashed mixed powder into 80 parts by weight of 75% alcohol, and soaking for 23 days.
EXAMPLE III
A pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus comprises the following raw materials in parts by weight: 20 parts of radix rehmanniae, 20 parts of radix scrophulariae, 20 parts of honeysuckle, 20 parts of radix isatidis, 20 parts of sculellaria barbata, 20 parts of cape jasmine, 20 parts of cortex moutan, 20 parts of salvia miltiorrhiza, 18 parts of semen plantaginis and 20 parts of oriental wormwood.
The preparation method of the pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus comprises the following steps:
(1) putting the dried rehmannia root, the figwort root, the honeysuckle, the isatis root, the barbed skullcap herb, the gardenia, the cortex moutan, the salvia miltiorrhiza bunge, the plantain seed and the oriental wormwood in the stone mortar according to the weight parts, and pounding the mixture into powder;
(2) the mashed mixed powder is put into 100 parts by weight of alcohol with the concentration of 75 percent for soaking for 25 days.
The use method of the above embodiment of the invention is as follows: when in use, the pure traditional Chinese medicine transdermal liniment is rubbed on skin acupoints of the whole body except the head, 3 times a day, and 40 days is a treatment course.
Clinical trial
1. Basic information
Selecting 70 patients with confirmed lupus erythematosus, wherein the age distribution is 25-45 years, the disease course is longest for 2 years, the shortest for 2 months, and the symptoms of the patients are as follows: the skin has a plurality of fresh red spots or nodules, and the whole body is lack of strength, alopecia, abnormal urine and the like.
2. Test method
Setting seven groups of test examples, namely example one, example two, example three, comparison example one, comparison example two, comparison example three and comparison example four, wherein each group of test examples is randomly distributed with 10 persons, and each group of test examples is respectively treated with the corresponding medicaments of the group for 80 days;
the comparative example is that the raw materials in the first example are replaced by: 15 parts of isatis root, 12 parts of barbed skullcap herb, 15 parts of gardenia, 12 parts of cortex moutan, 13 parts of salvia miltiorrhiza, 12 parts of plantain seed and 15 parts of oriental wormwood.
The second comparative example replaces the raw materials in the second example with: 17 parts of dried rehmannia root, 15 parts of figwort root, 17 parts of honeysuckle flower, 17 parts of cortex moutan, 16 parts of salvia miltiorrhiza bunge, 15 parts of plantain seed and 18 parts of oriental wormwood.
In a third comparative example, the raw materials in the third example are replaced by: 20 parts of radix rehmanniae, 20 parts of radix scrophulariae, 20 parts of honeysuckle, 20 parts of radix isatidis, 20 parts of sculellaria barbata, 20 parts of cape jasmine and 20 parts of cortex moutan.
In the fourth comparative example, the raw materials in the first example are replaced by: 3 parts of radix rehmanniae, 2 parts of radix scrophulariae, 5 parts of honeysuckle, 3 parts of radix isatidis, 4 parts of sculellaria barbata, 1 part of gardenia, 3 parts of cortex moutan, 3 parts of salvia miltiorrhiza, 2 parts of semen plantaginis and 5 parts of oriental wormwood.
3. Judgment of therapeutic effect
The therapeutic effect judgment standard is divided into four grades of cure, obvious effect, effective and ineffective.
And (3) curing: has no clinical symptoms.
The effect is shown: the clinical symptoms are mostly eliminated.
The method has the following advantages: the clinical symptoms are relieved.
And (4) invalidation: there was no change in clinical symptom manifestation.
4. Test results
| Test examples | Total number of people | The number of people cured | Number of effective people | Number of effective persons | Number of invalid persons |
| Example one | 10 | 5 | 2 | 2 | 1 |
| Example two | 10 | 7 | 2 | 1 | 0 |
| EXAMPLE III | 10 | 6 | 1 | 2 | 1 |
| Comparison example 1 | 10 | 0 | 2 | 3 | 5 |
| Comparative example two | 10 | 1 | 1 | 1 | 7 |
| Comparative example three | 10 | 1 | 1 | 2 | 6 |
| Comparative example four | 10 | 2 | 2 | 2 | 4 |
The pure traditional Chinese medicine transdermal liniment has obvious curative effect on treating lupus erythematosus.
Typical case 1
When a woman is in 28 years old, a plurality of fresh red spots appear on the skin, the lupus erythematosus is diagnosed by a hospital, western medicines are taken for treatment at first, the side effect is serious, and the symptom is not reduced, the pure traditional Chinese medicine transdermal liniment prepared by the invention is used for 3 times per day, a treatment course is continuously used, the symptom is reduced, the symptom disappears after the treatment course is continuously used, and the lupus erythematosus of a patient is cured after the hospital diagnosis.
Typical case 2
After the pure traditional Chinese medicine transdermal liniment prepared by the invention is used, the liniment is applied for 3 times every day, one treatment course is continuously used, the symptoms are relieved, the two treatment courses are continuously used, the symptoms disappear, and the lupus erythematosus of a patient is cured after the hospital diagnosis.
Typical case 3
After the pure traditional Chinese medicine transdermal liniment prepared by the invention is used, the pure traditional Chinese medicine transdermal liniment is applied for 3 times every day, one treatment course is continuously used, the symptoms are relieved, the three treatment courses are continuously used, the symptoms disappear, and the lupus erythematosus of a patient is cured after the hospital diagnosis.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (6)
1. A pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus is characterized by comprising the following raw materials in parts by weight: 14-20 parts of radix rehmanniae, 12-20 parts of radix scrophulariae, 15-20 parts of honeysuckle, 15-20 parts of radix isatidis, 12-20 parts of herba scutellariae barbatae, 15-20 parts of cape jasmine, 12-20 parts of cortex moutan, 13-20 parts of salvia miltiorrhiza, 12-18 parts of semen plantaginis and 15-20 parts of oriental wormwood.
2. The pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus, according to claim 1, is characterized by comprising the following raw materials in parts by weight: 14 parts of radix rehmanniae, 12 parts of radix scrophulariae, 15 parts of honeysuckle, 15 parts of radix isatidis, 12 parts of sculellaria barbata, 15 parts of cape jasmine, 12 parts of cortex moutan, 13 parts of salvia miltiorrhiza, 12 parts of semen plantaginis and 15 parts of oriental wormwood.
3. The pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus, according to claim 1, is characterized by comprising the following raw materials in parts by weight: 17 parts of radix rehmanniae, 15 parts of radix scrophulariae, 17 parts of honeysuckle, 17 parts of radix isatidis, 16 parts of sculellaria barbata, 18 parts of cape jasmine, 17 parts of cortex moutan, 16 parts of salvia miltiorrhiza, 15 parts of semen plantaginis and 18 parts of oriental wormwood.
4. The pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus, according to claim 1, is characterized by comprising the following raw materials in parts by weight: 20 parts of radix rehmanniae, 20 parts of radix scrophulariae, 20 parts of honeysuckle, 20 parts of radix isatidis, 20 parts of sculellaria barbata, 20 parts of cape jasmine, 20 parts of cortex moutan, 20 parts of salvia miltiorrhiza, 18 parts of semen plantaginis and 20 parts of oriental wormwood.
5. A method for preparing a pure Chinese medicinal transdermal liniment for treating lupus erythematosus as claimed in any one of claims 1 to 4, which comprises the following steps:
(1) putting the dried rehmannia root, the figwort root, the honeysuckle, the isatis root, the barbed skullcap herb, the gardenia, the cortex moutan, the salvia miltiorrhiza bunge, the plantain seed and the oriental wormwood in the stone mortar according to the weight parts, and pounding the mixture into powder;
(2) the mashed mixed powder is put into 50 to 100 weight parts of alcohol to be soaked for 20 to 25 days for use.
6. The preparation method of the pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus, which is characterized by comprising the following steps: the concentration of the alcohol in the step (2) is 75%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110023053.5A CN112587587A (en) | 2021-01-08 | 2021-01-08 | Preparation method of pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110023053.5A CN112587587A (en) | 2021-01-08 | 2021-01-08 | Preparation method of pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112587587A true CN112587587A (en) | 2021-04-02 |
Family
ID=75207063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110023053.5A Pending CN112587587A (en) | 2021-01-08 | 2021-01-08 | Preparation method of pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112587587A (en) |
-
2021
- 2021-01-08 CN CN202110023053.5A patent/CN112587587A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066442A (en) | Externally applied Chinese medicine lotion for treating pain caused by wind, cold and damp | |
| CN102552773A (en) | Drug for treating bronchitis and bronchial asthma of 7-15 year old children | |
| CN105169133B (en) | Treat the Chinese medicine preparation of psoriasis | |
| CN101129872A (en) | Powder of phellodendron amurense adlay erysipelas | |
| CN104800700A (en) | Chinese herbal medicine composition for treating skin diseases | |
| CN101322775B (en) | Chinese medicine for treating psoriasis | |
| CN101168032B (en) | Medicine for treating asthma | |
| CN112587587A (en) | Preparation method of pure traditional Chinese medicine transdermal liniment for treating lupus erythematosus | |
| CN104873911B (en) | A kind of pyemic traditional Chinese medicine for oral administration of auxiliary treatment | |
| CN100579572C (en) | Orally-administered Chinese medicinal composition for treating migraine pain | |
| CN103550615B (en) | Traditional Chinese medicine for treating spleen-kidney deficiency scouring disease | |
| CN112972557A (en) | Medicinal liquor for treating arthralgia and myalgia and preparation method thereof | |
| CN102846986A (en) | Traditional Chinese medicinal preparation for treating acute pyelonephritis | |
| CN102225118A (en) | Blood-activating wind-dispelling liquid | |
| CN105311460A (en) | Traditional Chinese medicine for treating vascular neuralgia headache | |
| CN110201059A (en) | A kind of Chinese medicine composition and preparation method thereof for treating skin allergy and nettle rash | |
| CN1297309C (en) | External medicine composition for curing arthralgia-syndrome of joint and preparation process thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN1308952A (en) | Chinese medicine for treating trigeminal neuraligia and its preparing process | |
| CN112274596A (en) | Pure traditional Chinese medicine transdermal liniment for treating gastric cancer and preparation method thereof | |
| CN1110604A (en) | Medicinal liquor for treatment of arthritis and promoting collateral and channels | |
| CN112494618A (en) | Pure traditional Chinese medicine transdermal liniment for treating syphilis of women and preparation method thereof | |
| CN105412889A (en) | Traditional Chinese medicinal honeyed pill for treating lumbar intervertebral disc protrusion, and preparation method thereof | |
| CN105213985A (en) | A kind of Chinese medicine decoction for the treatment of syndrome of marrow depletion due to kidney deficiency type cranial tinnitus | |
| CN117771166A (en) | Traditional Chinese medicine ointment for treating targeted drug-related rash as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210402 |
|
| WD01 | Invention patent application deemed withdrawn after publication |